NCT05849857View on ClinicalTrials.gov

Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

August 31, 2028

Conditions
Lymphoma, Follicular
Interventions
DRUG

Mosunetuzumab

Mosunetuzumab is administered as a subcutaneous injection. The first dose is 5 mg in 0,5 mL volume, subsequent doses are 45 mg in 1,0 mL volume.

Trial Locations (3)

Unknown

RECRUITING

Helsinki University Hospital, Helsinki

RECRUITING

St. Olavs hospital, Trondheim

0424

RECRUITING

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Aarhus University Hospital

OTHER

lead

Oslo University Hospital

OTHER